Wednesday, September 16, 2026 |
‘Mirzapur: The Movie’ crosses Rs 100 crore at domestic box office in opening weekendAmitabh Bachchan admits difficulty decoding Gen Z slangWatch: Nagarjuna releases trailer of Allari Naresh-starrer ‘Ramba Oorvasi Menaka’“Tum bahut lambe ho…”: Big B shares struggles of early acting daysNayanthara reveals how Geethu Mohandas convinced her to join ‘Toxic’Sonu Nigam says childhood anger fuelled his passion and shaped his singing careerYash takes out extra time time to pose for selfies with fans before leaving Mumbai airportRavi Teja begins dubbing for ‘Irumudi’, set for Aug 21 releaseDhanush did not enter cinema willingly and cried on his debut set, reveals father Kasthuri RajaBollywood stars shower blessings on Anshula Kapoor Rohan Thakkar at wedding reception

Biological E gets drug regulator's approval to conduct phase 2/3 trials on children

Posted September 2nd, 2021, 10:12 AM IST

Biological E gets drug regulator's approval to conduct phase 2/3 trials on children

The Drug Controller General of India (DCGI) on Wednesday granted permission to Hyderabad-based Biological E Limited to conduct Phase 2 & 3 clinical trials for its anti-COVID shots called Corbevax on children between 5 and 18 years of age with certain conditions, sources told ANI.

The trial will be conducted in ten locations.





The permission has been given to Biological E after the recommendation from the Subject Expert Committee.

Meanwhile, Zydus Cadila's needle-free COVID-19 vaccine ZyCoV-D has already received emergency use authorisation (EUA) to inoculate children in the age group of 12-18. It is expected to be administered from the first week of October.

The trials of Bharat Biotech's Covaxin COVID-19 vaccine for phases 2 & 3 for children are underway, and its result is expected in September.

It is to be noted that the government has made an advance payment of Rs 1,500 crore to Biological E for 30 crore vaccines.

Sharing

advertisement
Videos